Aurobin, ointment 20 g

Anal itching, Anal fissures, Skin lesions, HemorrhoidsProcesses accompanied by perianal inflammation, anal itching, eczema and dermatitis of the perianal area, fissures, hemorrhoids, anal fistula.

Active ingredient

Composition

1 g ointment contains:

the active ingredients:

prednisolone capronate 2 mg,

lidocaine hydrochloride 20 mg,

D-panthenol 20 mg;

excipients:

Polysorbate 60,

Triclosan,

Methylparahydroxybenzoate, neutral oil,

stearic acid,

purified water.

How to take, the dosage

Interaction

Special Instructions

Long-term therapy should be avoided if possible, especially in children, because of possible suppression of adrenal function. In children the drug can be used with caution, in the minimum dose to achieve the therapeutic effect. The duration of therapy in children should not exceed 5 days.

Any accidental contact with the eye or periorbital area should be avoided.

In case of contact, flush with water.

The development or spread of a secondary infection requires discontinuation of the drug and administration of antimicrobial or antifungal therapy. Bacterial infection is sustained in warm moist conditions, so the skin should be cleaned before each application of the ointment.

Application over a large surface area or use over a long period of time may lead to systemic absorption of the active ingredients. Prolonged use in one area may cause skin atrophy, especially in younger individuals.

The drug’s effect on driving and operating machinery

There are no data on the effect of Aurobin® affecting driving ability or working in high attention environments.

Contraindications

Side effects

Overdose

Pregnancy use

There are no data on safety and efficacy of the drug administration in pregnancy, therefore it is not recommended to prescribe Aurobin in the first trimester of pregnancy.

In the second and third trimesters of pregnancy, if it is necessary to use the drug, the estimated benefit to the mother and the potential risk to the fetus should be weighed.

Breast-feeding period: corticosteroids and lidocaine penetrate the mother’s milk, so if the drug has to be used during lactation, consideration should be given to stopping breast-feeding.